688763-65-7

Elubrixin, also known as SB-656933 or SB-656933-AAF, is a interleukin 8 inhibitor and CXCR2 selective antagonist, which is potentially useful for Inflammatory bowel disease therapies. Elubrixin inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. demonstrates dose-dependent effects on neutrophil activation and recruitment within a well-tolerated dose range. SB-656933 may be an effective agent in neutrophil-predominant diseases.

Elubrixin (SB-656933) hydrochloride 是一种有效，选择性，竞争性，可逆和具有口服活性的 CXCR2 拮抗剂和 IL-8 受体拮抗剂。Elubrixin hydrochloride 抑制中性粒细胞 CD11b 上调 (IC50 为 260.7 nM) 和形状改变 (IC50 为 310.5 nM)。Elubrixin hydrochloride 可用于炎症性疾病的研究，例如炎症性肠病和气道炎症。